Conversion to Combined Mycophenolate Mofetil and Low-Dose Calcineurin Inhibitor Therapy for Renal Dysfunction in Liver Transplant Patients: Never Too Late?-Reference-Cited by-同舟云学术

Conversion to Combined Mycophenolate Mofetil and Low-Dose Calcineurin Inhibitor Therapy for Renal Dysfunction in Liver Transplant Patients: Never Too Late?

Published:2010-11-04 Issue:1 Volume:56 Page:4-6
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Beckebaum Susanne,Cicinnati Vito R.

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://www.springerlink.com/index/pdf/10.1007/s10620-010-1449-1

Reference24 articles.

1. Sethi A, Stravitz RT. Review article: Medical management of the liver transplant recipient—A primer for non-transplant doctors. Aliment Pharmacol Ther. 2007;25:229–245.

2. Bahirwani R, Reddy KR. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl. 2009;15(Suppl 2):S70–S74.

3. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508.

4. Farkas SA, Schnitzbauer AA, Kirchner G, et al. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int. 2009;22:49–60.

5. Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation. 2007;83:1141–1150.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunosuppression and Treatment of Rejection in Uterus Transplantation: Current Practice and Future Potential;Uterus Transplantation;2019-12-01

2. Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors?;Liver International;2013-02-27